only marginally significantp = 0.06
An analysis stratified by cetuximab use confirmed previous findings: the risk of not achieving pCR was 2.17 (95% CI: 1.41–3.33) in patients not treated with cetuximab compared to 0.89 (95% CI: 0.39–2.05) in patients treated with cetuximab; however, this difference was only marginally significant ( p = 0.06). 3.2.2.